医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial-scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD-MAP)

2020年05月29日 AM04:02
このエントリーをはてなブックマークに追加


 

ALLMERSBACH IM TAL, Germany & CAMBRIDGE, Mass. & BRISBANE, Australia

Harro Höfliger, a global leader in pharmaceutical process engineering and sterile manufacture, and Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced an alliance to develop the world’s first high-throughput, aseptic manufacturing line for production of vaccine products based on Vaxxas’ HD-MAP technology. Single, aseptic-based lines will have a targeted throughput of up to 5 million vaccine products/week. Initial efforts are focused on a pilot line operating in 2021 to be used to support late-stage clinical studies.

“We’re excited to be working on this project with Harro Höfliger,” said David L. Hoey, President and CEO of Vaxxas. “A major challenge in commercializing microarray patches – like Vaxxas’ HD-MAP – for vaccination is the ability to manufacture at industrially-relevant scale, while meeting stringent sterility and quality standards. Our novel device design along with our innovative vaccine coating and quality verification technologies are an excellent fit for integration with Harro Höfliger’s aseptic process automation platforms. Adopting a modular approach, it will be possible to achieve output of tens-of-millions of vaccine-HD-MAP products per week.”

Vaxxas HD-MAP is a 9x9mm array of thousands of very short (~250µm) projections, invisible to the naked eye, coated with vaccine. Application of the HD-MAP to the skin quickly delivers vaccine to abundant populations of immune cells. In a recent clinical study, the HD-MAP demonstrated that 1/6 dose of influenza vaccine by Vaxxas’ HD-MAP resulted in comparable immune response to full dose by intramuscular injection and 2/3 dose by HD-MAP was capable of generating significantly faster and higher overall antibody responses. Because vaccine is dried onto the HD-MAP, vaccines can be stable outside of cold-chain; vaccines in the clinical study were verified to be stable at 40oC for 12 months.

“Harro Höfliger has an extensive track-record of bringing new pharmaceutical and medical device technologies from lab-scale to the production levels necessary for industry,” said Thomas Weller, CEO of Harro Höfliger. “Sterile processing adds additional complexity and our engineering development team and aseptic experts have a lot of experience in the development of new and customized processes for fully automated equipment in an aseptic environment. We’re looking forward to developing high-throughput aseptic production lines for the HD-MAP with the team at Vaxxas.”

For routine infectious disease more than 750 million vaccinations are given worldwide each year by needle/syringe in advanced markets as well as lower- and middle-income countries. In the case of pandemic response, billions of vaccinations may need to occur in a variety of settings. Vaxxas’ HD-MAP has the potential to create new needle-free vaccine products with enhanced immune response and designed for improved safety, storage, and distribution logistics to extend the reach of vaccines and improve vaccination efficiency and effectiveness.

About Harro Höfliger:

Harro Höfliger specializes in the development of customer-oriented process and production solutions for pharmaceutical and medical applications as well as market-oriented consumer products. In addition to innovative machine platforms and packaging machines, customized turnkey system solutions for product assembly, processing of web materials, as well as dosing and inhalation technology are the company’s core expertise. Furthermore, Harro Höfliger offers extensive services related to process development. The systematically structured portfolio of up scalable test machines and modules, as well as requirement-oriented technology platforms, results from many years of experience and targeted research and development.

About Vaxxas

Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary HD-MAP technology platform, which uses an ultra-high density array of projections – invisible to the naked human eye – applied to the skin to rapidly deliver vaccine to the abundant immune cells immediately below the skin surface. This approach can enhance efficiency and effectiveness of immune response. Vaxxas uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation – easing the resource and logistics burden of maintaining the “cold chain.” Leveraging the potent immunogenic response and thermostability of HD-MAP, Vaxxas is targeting initial applications in infectious disease and oncology.

Vaxxas core technology was developed at the University of Queensland. The company was founded with the completion of an initial equity financing led by OneVentures Innovation Fund I with co-investors Brandon Capital, the Medical Research Commercialisation Fund (MRCF), and US-based HealthCare Ventures, followed by a further financing led by OneVentures. OneVentures Innovation Fund I and the MRCF are supported by the Australian Government’s Innovation Investment Fund (IIF) program. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies. Learn more at www.one-ventures.com and www.brandoncapital.com.au.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005295/en/

CONTACT

Michaella Porter

WE Communications

Ph: +61 488 217 191

mporter@we-worldwide.com

Amy Miller

WE Communications

Ph: +61 431 072 422

amymi@we-worldwide.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • KKR to Acquire a Controlling Stake in J.B. Chemicals & Pharmaceuticals
  • Urethral Stricture Treatment by Hybrid Cell Therapy, Granted Japanese Patent
  • ABEC制造工厂获得OSHA颁发的SHARP认证
  • Thomas Launches New Certified Thomas Agency Program
  • Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer